New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 11, 2013
12:19 EDTKOG, AMD, MACK, MSFT, BPIOn The Fly: Midday Wrap
Stocks on Wall Street were higher at midday as the S&P 500 eclipsed its all-time closing high and stood within points of its record intraday high. The strength in the equity markets comes after Federal Reserve Chairman Ben Bernanke gave a speech in Massachusetts yesterday afternoon. During his Q&A session, Bernanke noted that that even though the Fed may begin reducing its bond buying soon, interest rates will stay pinned at their current low levels for a long time. The chairman also pointed out that the unemployment rate probably understates the weakness in the labor market evidenced by other measures, such as the labor participation rate. Though Bernanke may not have intended to deliver a major monetary message, investors appear to be receiving it as such, driving the averages higher again. ECONOMIC EVENTS: In the U.S., initial jobless claims in the week ended July 6 jumped a more-than-expected 16K to 360K. Import prices fell 0.2% from the prior month in June, versus expectations for them to be flat. COMPANY NEWS: Microsoft (MSFT) announced the details of what the company called its "One Microsoft" reorganization plan. The new structure focuses the company’s engineering efforts around four areas: OS, Apps, Cloud, and Devices. Also of note, the company's Windows and Office products will fall under new leadership following the realignment. On a down note for the software maker was data released last night by market researcher Gartner that showed second quarter global PC shipments fell 10.9% to 76M, while another researcher, IDC, pegged the decline at 11.4%. MAJOR MOVERS: Among the notable gainers was Bridgepoint Education (BPI), which surged 20% after the company's flagship college, Ashford University, was granted accreditation, after having been denied accreditation last year. Also higher were shares of Advanced Micro Devices (AMD), which rose nearly 10% following upgrades at two Street research firms. Among the noteworthy losers was Merrimack Pharmaceuticals (MACK), which fell 20% after the company filed to sell $50M in common stock and $75M in convertible senior notes. Also lower was Kodiak Oil & Gas (KOG), which slid more than 2% after The Wall Street Journal said, citing sources, that the company had hired bankers last year to field interest from possible takeover suitors, though talks with potential buyers did not result in a deal. INDICES: Near noon, the Dow was up 129.98, or 0.85%, to 15,421.64; the Nasdaq was up 41.83, or 1.19%, to 3,562.59; and the S&P 500 was up 16.15, or 0.98%, to 1,668.77.
News For MSFT;AMD;BPI;MACK;KOG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 27, 2015
05:55 EDTMSFTStocks with implied volatility below IV index mean; MSFT QCOM
Subscribe for More Information
February 26, 2015
14:02 EDTMSFTMicrosoft shutting down two factories in China, Want China Times reports
Subscribe for More Information
11:55 EDTMACKMerrimack pipeline progressing despite MM-111 discontinuation, says Cantor
Subscribe for More Information
11:49 EDTMACKMerrimack stops MM-111 development after DSMB recommendation
Subscribe for More Information
07:29 EDTMACKMerrimack reports Q4 EPS (9c), consensus (19c)
Reports Q4 revenue $33.91M, consensus $28.78M.
06:27 EDTMSFTMicrosoft increases orders to China makers, DigiTimes reports
Microsoft is increasing orders to China makers and away from Taiwan makers, reports DigiTimes. Microsoft has become increasingly concerned over costs and is adjusting its supply chain to receive components at more competitive pricing that previously received from Taiwan makers. Reference Link
06:13 EDTMSFTStocks with implied volatility below IV index mean; MSFT QCOM
Subscribe for More Information
February 25, 2015
10:34 EDTMSFTHP slide after currency driven guidance cut called buying opportunity
The shares of Hewlett-Packard (HPQ) are falling after the company reported lower than expected first quarter revenue and sharply lowered its free cash flow guidance and cut its fiscal year profit view. However, analysts at Citigroup, Bernstein, and Brean Capital all recommended buying the stock on weakness in separate notes to investors today. BACKGROUND: HP reported slightly higher than expected Q1 profits, but its revenue came in below expectations. The company sharply lowered its fiscal 2015 free cash flow guidance to $3.5B-$4B from its previous outlook of $6.5B-$7B. The tech giant also lowered its fiscal 2015 EPS guidance to $3.53-$3.73 from its previous outlook of $3.83-$4.30. "While we were able to manage the impact of currency in the quarter and deliver earnings as expected, we believe the impact on FY15 will be significantly greater than we anticipated in November. We'll work hard to offset these impacts through re-pricing and productivity, but fully mitigating currency movements of this size would require reducing investments and mortgaging our future. We won't do that," said HP CEO Meg Whitman. ANALYST REACTION: The decline in HP's EPS guidance was entirely due to foreign currency fluctuations, while most of the cut in its free cash flow guidance was caused by one-time costs related to the upcoming split of HP into two separate companies, Citi analyst Jim Suva stated. Most of the company's businesses "continue to perform well or at least make progress," wrote Suva. The decline in the stock has created an attractive entry point for investors who are looking to own the shares in order to benefit from the break-up, according to the analyst. He kept a Buy rating on the shares. Bernstein analyst A.M. Sacconaghi was less upbeat on HP's outlook, but also recommended buying the shares on today's weakness. Although revenue estimates for HP may be too high, the stock's valuation remains attractive, as it is the second least expensive tech stock in the S&P 500, according to Sacconaghi, who believes the shares are worth $45-$50. Cautioning that HP's stock is likely "to be in the penalty box" in the near-term, Sacconaghi nonetheless believes that the shares could get a significant boost when the company provides more information about its spin-off. He recommended that investors buy the stock on today's weakness and kept an Outperform rating on the shares. HP's fundamentals haven't changed, as the company continues to expect its revenue to remain flat in fiscal 2015, and it has not changed its capital return guidance, Brean Capital analyst Ananda Baruah stated. The company also continues to expect free cash flow of at least $5B-$6B in 2016 and beyond, Baruah added. Moreover, HP's share repurchases are unlikely to be significantly reduced as a result of the decline in its free cash flow guidance, the analyst predicted. Baruah recommended buying the stock on today's weakness and kept a $45 price target and Buy rating on the shares. PRICE ACTION: In early trading, HP fell 9.5% to $34.84. OTHERS TO WATCH: Other large cap PC levered names are also weak in morning trading after HP's report last night, with Microsoft (MSFT) down 0.25% and Intel (INTC) down 1.2%.
09:48 EDTMSFTIDC reports 96.3% smartphone marketshare for iPhone, Android
Subscribe for More Information
05:54 EDTMSFTStocks with implied volatility below IV index mean; FOSL QCOM
Subscribe for More Information
February 24, 2015
07:28 EDTAMDAMD management to meet with Deutsche Bank
Meeting to be held in New York on February 24 hosted by Deutsche Bank.
February 23, 2015
09:59 EDTAMDOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:46 EDTAMDAMD initiated with an Underperform at Exane BNP Paribas
Target $2.30.
February 19, 2015
08:17 EDTMACKMerrimack initiates Phase 2 biomarker-selected clinical trial of MM-121
Merrimack Pharmaceuticals announced the initiation of a global, open-label, biomarker-selected, randomized Phase 2 clinical trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive, locally advanced or metastatic non-small cell lung cancer. As part of this trial, Merrimack expects to enroll approximately 120 heregulin positive patients that will be randomized to receive either MM-121 plus the investigator's choice of docetaxel or pemetrexed, or the investigator's choice of docetaxel or pemetrexed alone.
February 18, 2015
16:27 EDTMSFTiPass announces Wi-Fi agreement with Microsoft
Subscribe for More Information
10:18 EDTMSFTInterDigital drops after reportedly lossing appeal in patent case
Shares of InterDigital (IDCC) are moving lower after Bloomberg reported the company lost its bid to revive patent-infringement claims against Microsoft (MSFT) and ZTE Corp. over mobile phone technologies. Shares of InterDigital are down 83c to $50.06.
05:57 EDTMSFTStocks with implied volatility below IV index mean; MSFT QCOM
Subscribe for More Information
February 17, 2015
09:09 EDTMSFTBox announces Microsoft Office cloud integration
Subscribe for More Information
09:06 EDTMSFTCitrix joins Microsoft Cloud Storage Partner Program
Citrix (CTXS) announced it is an inaugural member of the new Microsoft (MSFT) Cloud Storage Partner Program.
05:51 EDTMSFTStocks with implied volatility below IV index mean; MSFT QCOM
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use